Last €76.69 EUR
Change Today -1.20 / -1.54%
Volume 0.0
LO3 On Other Exchanges
Symbol
Exchange
SIX Swiss Ex
OTC US
Singapore
Frankfurt
OTC US
As of 1:47 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-reg (LO3) Snapshot

Open
€77.75
Previous Close
€77.89
Day High
€78.25
Day Low
€76.69
52 Week High
06/19/14 - €82.31
52 Week Low
09/2/13 - €51.57
Market Cap
4.1B
Average Volume 10 Days
234.0
EPS TTM
--
Shares Outstanding
52.9M
EX-Date
04/22/14
P/E TM
--
Dividend
€2.14
Dividend Yield
2.29%
Current Stock Chart for LONZA GROUP AG-REG (LO3)

Related News

No related news articles were found.

lonza group ag-reg (LO3) Related Businessweek News

View More BusinessWeek News

lonza group ag-reg (LO3) Details

Lonza Group Ltd. supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. It operates in two segments, Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech segment develops and manufactures active pharmaceutical ingredients (APIs) for drug companies; microbial parenteral API, including antibody fragments, vaccines, cytokines, plasmid DNA, fusion proteins, and PEGylated products; and chemical custom services, such as chemically derived active ingredients, antibody drug conjugates, and cytotoxic and peptide syntheses, as well as biological cellular and gene therapies. This segment also offers cell culture, transfection, and molecular biology tools for lifescience research; media used in the production of therapeutics; endotoxin detection assays; products and services targeting cardiovascular, respiratory, neurological, metabolic, cancer, and other disease research areas; and cell biology solutions to enhance efficiencies in research. This segment serves customers in academic and government institutions, and in biotech and pharmaceutical organizations. The Specialty Ingredients segment offers personal care and preservation products comprising actives for antidandruff shampoos, and natural and organic cosmetic ingredients; vitamin B3 compounds and L-Carnitine, as well as nutritional ingredients used in pharmaceuticals, human energy drinks, and animal feeds; and microbial control solutions, including disinfectants and sanitizers that protect from dangerous and unwanted microbes. This segment also provides custom agricultural manufacturing services to enhance crop yields; sanitizers and other treatment chemicals, as well as feeder systems for drinking water disinfection and surface-water treatments; industrial Solutions, such as preservatives and biocide blends; and products and services that enhance the quality of wood. The company was founded in 1897 and is headquartered in Basel, Switzerland.

9,935 Employees
Last Reported Date: 03/20/14
Founded in 1897

lonza group ag-reg (LO3) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

lonza group ag-reg (LO3) Key Developments

Lonza Invests in Singleuse Technology and Facility Upgrades for Clinical ADC Manufacturing

Lonza announced investment plans for technology and facility improvements to its Antibody Drug Conjugate (ADC) clinical manufacturing facility in Visp, Switzerland. The planned upgrades include the introduction of single-use technology for flexible ADC manufacturing, along with a recently optimized plant layout and revamping of the Heating, Ventilation, Air Conditioning systems, which has resulted in a larger ADC production area. The addition of single-use manufacturing systems will reduce potential product contamination risks and allow for increased manufacturing capacity of existing and novel ADC platforms. Currently, Lonza's clinical ADC plant in Visp produces toxicology lots, early-phase GMP lots and GMP re-supply lots to support ongoing clinical trials for several different product candidates. Oncology therapeutics represents one of the fastest-growing segments of the pharma and biotech industry, and the deployment of ADC targeted therapies has intensified in recent years. This growth has led to an increased clinical pipeline, which necessitated the expansion of manufacturing capacity and the utilization of new single-use technologies. ADC cGMP manufacturing facilities must be designed to handle both biological species and highly potent cytotoxic small organic molecule drugs. The Visp site will continue to offer integrated end-to-end development and manufacturing of ADCs, including the cytotoxic small organic molecules used in these products and all associated analytics. All current operations will continue without interruption.

Lonza Group Ltd Presents at Corporate Performance Management West Summit, Jun-18-2014 03:30 PM

Lonza Group Ltd Presents at Corporate Performance Management West Summit, Jun-18-2014 03:30 PM. Venue: San Diego Marriott Marquis & Marina, 333 West Harbor Drive, San Diego, California, United States. Speakers: Alexander Hoy, CFO.

Lonza Group Ltd Appoints Sven Abend as Member of the Company's Executive Committee Effective July 1, 2014

Lonza Group Ltd announced the appointment of Sven Abend as member of the company's Executive Committee effective July 1, 2014. Sven Abend, currently CEO of Kolb Ltd, will have primary responsibility for Corporate Strategy and Business Development, as well as Consumer Care and Industrial Solutions, and will ensure focused delivery of Lonza's growth strategy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LO3:GR €76.69 EUR -1.20

LO3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $72.00 USD +0.40
Ashland Inc $107.47 USD -0.12
Clariant AG SFr.17.03 CHF +0.15
Dr Reddy's Laboratories Ltd 2,701 INR 0.00
Piramal Enterprises Ltd 695.95 INR 0.00
View Industry Companies
 

Industry Analysis

LO3

Industry Average

Valuation LO3 Industry Range
Price/Earnings 55.9x
Price/Sales 1.4x
Price/Book 2.3x
Price/Cash Flow 56.7x
TEV/Sales 0.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-REG, please visit www.lonza.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.